Protected: Tailoring ROS1+ NSCLC Treatment: The Role of Biomarker Testing

1. Lung.org biomarker American Lung Association. Lung Cancer Biomarker Testing. Available at https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing. Accessed October 4, 2024.
2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), for Non-Small Cell Lung Cancer V.11.2024. ©National Comprehensive Cancer Network, In. 2024. All rights reserved. Accessed October 24, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. 
3. National Cancer Institute. Biomarker Testing for Cancer Treatment. Available at https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment. Accessed October 4, 2024.
4. Conde E, Rojo F, et al. Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing. J Clin Pathol. 2022 Mar;75(3):145-153.
5. Lung Cancer Foundation of America. What is ROS1-positive lung cancer and how is it treated? Available at https://lcfamerica.org/lung-cancer-info/types-lung-cancer/ros1-positive-lung-cancer/#1572536052547-0f2e7123-c8e8. Accessed October 4, 2024
6. Gosney J R, Paz-Ares L, et al. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation. ESMO Open. 2023 Aug;8(4):101587.
7. National Cancer Institute. Tumor board review. Available at https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tumor-board-review. Accessed October 4, 2024.
8. The ROS1ders. Treating stage 4 ROS1+ Cancer (For Patients). Available at https://www.theros1ders.org/treatment-options. Accessed October 4, 2024

© 2024 Turning Point Therapeutics, Inc., a Bristol Myers Squibb Company.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

NCCN=National Comprehensive Cancer Network® (NCCN®)

ONC-US-2400507 11/24